NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

RecruitingN/A

Sponsor: Haukeland University Hospital

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Blood samples for PK, Blood samples for PK

Countries: Norway

ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.

Eligibility overview

Sex: ALL

Age: 18 Years to 60 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Included in OVERLORD-MS (NCT04578639)
* Willing to attend laboratory for blood sample collection at scheduled time points

Exclusion criteria:

\* Not willing to attend laboratory for blood sample collection at scheduled time points

Locations (1)

Bergen, Vestland, Norway